Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression.
about
MicroRNAs: Novel Players in the Dialogue between Pancreatic Islets and Immune System in Autoimmune DiabetesMicroRNAs as pharmacological targets in diabetesMicroRNAs in autoimmune diseasesThe Role of MicroRNAs in Diabetic Complications-Special Emphasis on Wound HealingIssues and prospects of microRNA-based biomarkers in blood and other body fluidsThe two faces of miR-29The pathogenic role of persistent milk signaling in mTORC1- and milk-microRNA-driven type 2 diabetes mellitusInhibition of Autoimmune Diabetes in NOD Mice by miRNA TherapyInhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardiumArsenic responsive microRNAs in vivo and their potential involvement in arsenic-induced oxidative stressRegulation of cardiac expression of the diabetic marker microRNA miR-29MicroRNA Expression Varies according to Glucose Tolerance, Measurement Platform, and Biological Source.miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunityEnvironmental exposures in utero and microRNA.Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseasesIdentifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients.Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review.MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasismiR-375 gene dosage in pancreatic β-cells: implications for regulation of β-cell mass and biomarker developmentBlood-based signatures in type 1 diabetes.The microRNA-148/152 family: multi-faceted playersMicroRNA-27a Induces Mesangial Cell Injury by Targeting of PPARγ, and its In Vivo Knockdown Prevents Progression of Diabetic NephropathyPost-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19bRegulation of human adipogenesis by miR125b-5pA Presenilin/Notch1 pathway regulated by miR-375, miR-30a, and miR-34a mediates glucotoxicity induced-pancreatic beta cell apoptosis.MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy.Profiling of circulating microRNAs in children with recent onset of type 1 diabetes.Alpinia oxyphylla Miq. extract changes miRNA expression profiles in db-/db- mouse kidneyCardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease.Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes.Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes.MicroRNAs: Biomarkers, Diagnostics, and Therapeutics.Nucleic acid biomarkers of β cell stress and death in type 1 diabetes.Biomarkers of β-Cell Stress and Death in Type 1 Diabetes.MicroRNAs in Type 1 Diabetes: Complex Interregulation of the Immune System, β Cell Function and Viral Infections.Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy.microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases.Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus.
P2860
Q26784462-D551622F-E522-4F20-B7FF-1833E7FC59EFQ26824024-981316FF-51EF-4AE8-A9C6-A6E895E4033AQ26824814-A140E98F-F04F-4742-80A6-B8E7EA89402DQ26827627-32A01978-8DE5-4C47-9D47-4BDFA0A3532FQ26991755-55DB28D8-4170-40C9-A668-25382EEDB452Q26996481-3096F405-86B0-4E07-8FAD-DA9CFE5F3D94Q27027262-41C2DE90-617C-4CD3-B8E9-C7B6A3307D4BQ27334532-3114A840-E4FC-4509-A322-969E018197B3Q28305306-74D01945-2771-4C19-AC9A-4761C18FC5C2Q28389940-8C955EFE-24A2-40FF-AFEB-9A88A031CBE3Q28541217-C6DF768F-E1DA-403F-AD78-0B86784A8861Q33654397-6A26E9D2-0904-427F-9CF4-0F621D4E4F82Q33920162-B1A5A58A-A912-49CD-A553-70BDD706FF80Q34155591-E034C61A-34B4-46A0-A4A5-015F02E4584BQ34252480-A87B0304-BD0D-4DA5-8573-0BB7751196B4Q34391443-12732CAB-813A-4FDF-B751-ED47592D4C97Q34461828-B211D1EF-F412-4473-8728-1EEE4B2972AEQ35674747-8CB9CA03-16B4-4C43-8086-12BD98EFB692Q36075377-7875D58B-3A9E-4A24-BE2A-4DB9FA520A30Q36109279-76D3F3D4-DBD4-4A5E-AD39-13FF5DAD8088Q36552481-71EDDCC1-84B9-409A-820D-EAF2CA019788Q36898251-81EED5F6-E702-40A5-B0C0-46A4B2D19A8BQ36906818-38F88214-3122-4EA7-BF89-73A189A8B366Q37218177-7C3C7BE6-1758-4845-8A2B-6C16BA165B1CQ37237968-4D835F40-1328-4560-955E-D0D140BB6025Q37393515-A9EFC9CC-2B3D-486B-A8B6-756D26C08C4BQ37565264-13C13DD9-220D-49D1-A396-AFE9C2AA07EFQ37646903-B4A4621F-82E1-4CCF-AD21-C2F9B4821129Q37673402-637529B4-577E-49EB-8052-6C96535B65B4Q37685243-5EC61EB8-DD0D-40BA-95C8-F460706D1E89Q38429701-B633FBA9-2AF3-4694-845C-115080840281Q38684417-0CEAB9A8-F9A1-4E8E-9204-8040C10CB199Q38765883-76CD679D-84DD-4A1D-A121-C55544CCFD44Q38851586-75E55609-EFD9-4B1B-85EE-41F75B73763DQ38931848-D1445A95-6D7C-4E56-85EC-357F174E3987Q39008865-78F891C3-6EEB-4CE6-9418-14B308013C8DQ39141563-451F9996-C118-436D-A60B-FC1745D636DDQ39190427-9577125F-DDAE-4B79-A6AF-8DC90E60B166Q39403789-9FADA46B-976C-4DC1-B584-A50543DAA083Q40374047-93161488-6B0D-44B3-82CD-BF1AD39B121E
P2860
Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Circulating levels of microRNA ...... ol during disease progression.
@ast
Circulating levels of microRNA ...... ol during disease progression.
@en
type
label
Circulating levels of microRNA ...... ol during disease progression.
@ast
Circulating levels of microRNA ...... ol during disease progression.
@en
prefLabel
Circulating levels of microRNA ...... ol during disease progression.
@ast
Circulating levels of microRNA ...... ol during disease progression.
@en
P2093
P2860
P50
P356
P1476
Circulating levels of microRNA ...... rol during disease progression
@en
P2093
Chen-Yu Zhang
Kaspar Sørensen
Lars Hansen
Lotte B Nielsen
Marie-Louise M Andersen
Philip Hougaard
P2860
P304
P356
10.1155/2012/896362
P577
2012-07-05T00:00:00Z